ArticleMolecular medicine (Cambridge, Mass.)2026
Epigenetic and microRNA-mediated regulation of pulmonary fibrosis and immune dysregulation in fatal COVID-19.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSevere cases of COVID-19 can result in acute respiratory distress syndrome, extensive lung damage, and long-term structural changes, particularly extracellular matrix (ECM) remodeling. ECM remodeling is characterized by excessive collagen deposition and imbalanced activity of enzymes, such as matrix metalloproteinases. Although immune and inflammatory pathways in patients with COVID-19 are well understood, the epigenetic and post-transcriptional regulation is not well understood. In this exploratory study, we examined DNA methylation and miRNA-mediated regulation in lung tissues from fatal cases of COVID-19.
methodsMethods included gene and protein expression analyses, DNA methylation assays, evaluation of DNMT activity, MSP‒dPCR, miRNA profiling and pathway enrichment analysis.
resultsWe observed altered expression of ECM regulators, such as MMP2, MMP9 and ADAM33, as well as molecules related to SARS-CoV-2 infection, including ADAM17 and ACE2. Evidence of methylation-mediated regulation was observed for ADAM33 and ACE2. Two miRNAs were significantly downregulated (miR-16-5p and miR-30d-5p), whereas miR-19a-3p/19b-3p and miR-21-5p were upregulated. Pathway analysis revealed activation of p53, apoptosis, and growth factor related pathways, as well as the suppression of vascular, interferon and T-cell activation signaling pathways.
conclusionOverall, these findings suggest that, in this cohort of fatal COVID-19 cases, lung tissue exhibits features consistent with ECM remodeling, epithelial fibrosis, and immune dysregulation. Additionally, the results raise the possibility that epigenetic alterations and miRNA-mediated regulatory mechanisms may be associated with disease progression in severe cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.